Methods and Compositions for Enhancing Intranasal Delivery of Therapeutic Agents
AssigneeWisconsin Alumni Research Foundation
InventorsRobert Gary Thorne, Jeffrey James Lochhead
Life of this patent
Estimating the term…
Abstract
A method for treating a patient suffering from a condition with an active compound comprising the steps of (a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, wherein the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal lamina of the patient is partially digested and type IV collagen of the patient is degraded or wherein access to the patient's perineural, perivascular, or lymphatic compartment spaces is facilitated and (b) treating the patient intranasally with an active compound is disclosed.
Claims22
1-12. (canceled)
A therapeutic device comprising a nebulizer, sprayer or dropper charged with a preparation of MMP-9 or a functionally equivalent fragment.
19-20. (canceled)
An MMP-9 formulation for intranasal delivery, wherein the formulation comprises MMP-9 or a functionally equivalent fragment.
The MMP-9 formulation of 26, wherein biopharmaceuticals are selected from antibodies or antibody fragments, peptides, proteins, vectors for gene therapy, and/or stem cells and wherein macromolecules are selected from RNA, asRNA, siRNA, DNA, cDNA, and any other oligonucleotides, and therapeutic agents are selected from any other chemicals.
A kit for intranasal delivery comprising (1) a container or formulation wherein the container or formulation comprises MMP-9 or a functionally equivalent fragment and (2) means for delivering MMP-9.
Dependencies are inferred from the claim text.